We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Autolus Therapeutics Ltd (AUTL) ADS Each Rep 1 Ord Shs

Sell:$2.91 Buy:$3.22 Change: $0.1 (3.52%)
NASDAQ:0.16%
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$2.91
Buy:$3.22
Change: $0.1 (3.52%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$2.91
Buy:$3.22
Change: $0.1 (3.52%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Contact details

Address:
The Mediaworks, 191 Wood Lane
LONDON
W12 7FP
United Kingdom
Telephone:
+44 (20) 38296230
Website:
https://www.autolus.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AUTL
ISIN:
US05280R1005
Market cap:
$745.14 million
Shares in issue:
266.09 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Unclassified
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Bonney
    Chairman of the Board
  • Christian Itin
    Chief Executive Officer, Executive Director
  • Martin Pule
    Founder, Senior Vice President, Chief Scientific Officer
  • Lucinda Crabtree
    Chief Financial Officer, Senior Vice President
  • Christopher Vann
    Chief Operating Officer, Senior Vice President
  • Edgar Braendle
    Senior Vice President
  • David Brochu
    Senior Vice President, Chief Technical Officer
  • Brent Rice
    Senior Vice President, Chief Commercial Officer
  • Matthias Will
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.